About Oncxerna therapeutics
OncXerna Therapeutics: Advancing Precision Medicine to Improve Patient Lives
OncXerna Therapeutics is a biotechnology company that is dedicated to advancing state-of-the-art precision medicine to dramatically improve the lives of patients. The company was founded in 2017 by a team of experienced scientists and entrepreneurs who recognized the need for more effective cancer treatments.
At OncXerna, the focus is on developing innovative RNA-based technologies that can be used to identify and target specific cancer cells. This approach allows for more precise and personalized treatment options, which can lead to better outcomes for patients.
One of the key technologies being developed by OncXerna is called RNA-Sequencing (RNA-Seq). This technology allows researchers to analyze the entire transcriptome of a patient's tumor, which provides a comprehensive view of all gene expression patterns within the tumor. By analyzing this data, researchers can identify specific genetic mutations or alterations that are driving tumor growth. This information can then be used to develop targeted therapies that are tailored specifically to each patient's unique genetic profile.
In addition to RNA-Seq, OncXerna is also developing other cutting-edge technologies such as single-cell sequencing and liquid biopsy assays. These tools allow researchers to analyze individual cells within a tumor or detect circulating tumor DNA in a patient's blood sample. By using these techniques, researchers can gain even deeper insights into how tumors evolve over time and how they respond to different treatments.
OncXerna has already made significant progress in its mission to advance precision medicine. The company has established partnerships with leading academic institutions and pharmaceutical companies around the world, including collaborations with Memorial Sloan Kettering Cancer Center and Takeda Pharmaceuticals.
One of OncXerna's most promising drug candidates is ONC206, which targets an important protein called CRM1 that plays a critical role in cancer cell survival. Preclinical studies have shown that ONC206 has potent anti-tumor activity against a wide range of cancer types, including pancreatic, breast, and lung cancers. The drug is currently in Phase 1 clinical trials, and early results have been very promising.
Overall, OncXerna Therapeutics is a company that is at the forefront of precision medicine research. With its innovative RNA-based technologies and strong partnerships with leading institutions and companies, OncXerna has the potential to revolutionize cancer treatment and improve the lives of countless patients around the world.